Several lines of evidence, including expression analyses, brain imaging and genetic studies suggest that the integrity of myelin is disturbed in schizophrenia patients. In this study, we first reconstructed a pathway of 138 myelin-related genes, all involved in myelin structure, composition, development or maintenance. Then we performed a two-stage association analysis on these 138 genes using 771 single nucleotide polymorphisms (SNPs). Analysis of our data from 310 cases vs 880 controls demonstrated association of 10 SNPs from six genes. Specifically, we observed highly significant P-values for association in PIK4CA (observed P = 6.1 Â 10
Introduction
Schizophrenia (MIM 181500) is a severe and common psychiatric disorder with a lifetime risk of approximately 1%. Its etiology includes strong genetic factors characterized by a complex inheritance pattern. [1] [2] [3] Multiple lines of evidence suggest that the integrity of myelin is disturbed in schizophrenia patients and that such abnormalities may be causally involved in the disease pathogenesis-for a comprehensive review see Davis et al. 4 The three main lines of evidence are: (1) MRI and post-mortem studies show volume reductions and ultrastructural abnormalities in the white matter of the prefrontal cortex in schizophrenia patients. [5] [6] [7] [8] [9] [10] [11] [12] [13] (2) Gene expression profiling studies have demonstrated that several myelin-related genes are differentially expressed in post-mortem brain tissue of patients compared to unaffected controls. These genes include 2 0 -3 0 -cyclic nucleotide 3 0 -phosphodiesterase (CNP), V-ERB-B2 avian erythroblastic leukemia viral oncogene homologue 3 (ERBB3), gelsolin (GSN), myelin and lymphocyte protein (MAL), myelin-associated glycoprotein (MAG), myelin and lymphocyte protein (MLP) and transferin (TF). [14] [15] [16] [17] [18] (3) Myelination of the prefrontal cortex typically peaks in late adolescence and early adulthood, thus coinciding with the onset of symptoms of schizophrenia. Moreover, schizophrenia patients manifest symptoms similar to those observed in nonschizophrenia patients with prefrontal demyelination. 4 Together, the evidence suggests that myelin is involved in the pathology of schizophrenia and in this study we aimed to identify any genetic variants in myelin-related genes that contribute to susceptibility to schizophrenia in the Dutch population.
Based on extensive literature research, we reconstructed a pathway of myelin-related genes. While constructing this pathway, we noticed that several 'myelin-related' genes could also be linked to the phosphatidylinositol (PI) pathway. Genes from this pathway are mentioned repeatedly as probable candidate genes for schizophrenia and bipolar disorder in abstracts of World Congress of Psychiatric Genetics. 19 In a previous study, 20 we also identified an association between PIP5K2A and schizophrenia. We therefore decided to include 27 genes from the PI signaling system (KEGG pathway 21 ). The final pathway accordingly includes those genes that encode structural proteins, and proteins involved in phospholipid and glycolipid metabolism, as well as their regulatory genes. A well-defined set of tagSNPs was used to cover all genes in a thorough association screen. In this study, we report finding significant association of the chromosome 22q11 gene PIK4CA to the risk of developing schizophrenia, and suggestive association for five more myelin-related genes.
Materials and methods

Study design
An association study of myelin-related genes was performed in a two-stage approach. In stage 1, 771 tagSNPs were genotyped in cases and controls. In stage 2, the 17 single nucleotide polymorphisms (SNPs) with the most significant levels of association (Pp0.01) were genotyped in an additional cohort of controls. Data of both stages were jointly analyzed, as recommended by Skol et al. 22 Since a relatively large proportion of the samples were analyzed in stage 1 and the joint analysis made full use of the stage 1 data, the joint analysis is more powerful than a replication-based analysis.
Subjects
A cohort of 310 schizophrenia patients was recruited from psychiatric hospitals and relatives' support groups. All subjects were diagnosed with schizophrenia according to Diagnostic and Statistical Manual of Mental Disorders, fourth edition criteria by welltrained raters using the Comprehensive Assessment of Symptoms and History 23 on the basis of an interview and information from medical records. The diagnosis was based on consensus between two raters, with an inter-rater reliability for diagnostic consensus k > 0.9.
In total, we used 880 controls from two distinct cohorts. The first control cohort contained 104 healthy individuals recruited through the Department of Psychiatry, UMC Utrecht, and was used for stage 1. The second cohort comprised 776 random Caucasian donors from the blood bank, of which 416 were available for stage 1. Collection of the control samples was continued after the start of the experiments. For further interpretation and validation of our findings, an additional 360 controls were used in stage 2.
Allele frequency distributions of the control cohorts from the blood bank and the Department of Psychiatry, UMC Utrecht were compared, resulting in 711 (autosomal) w 2 -values with a mean of 0.95 and a median of 0.46. These values do not deviate from a null distribution (with a mean B1 and a median B0.45). There was, therefore, no evidence of stratification and we expect both control groups to represent the general Dutch population. 24 All participants included in this study had at least three grandparents born in the Netherlands and their DNA was isolated from whole blood. They all gave written consent for their DNA to be used for research purposes. The study was approved by the Medical Ethics Committee of the University Medical Center Utrecht.
Statistical power
Relative risks for genes involved in schizophrenia are expected to be modest. In stage 1, our sample of 310 cases and 520 ( = 104 þ 416) controls had a statistical power of 92% to detect associations with a relative risk of 1.7 at an a level of 0.05. More stringent a levels of 0.01 and 6.49 Â 10 À5 ( = 0.05/771) correspond to 79 and 28% power, respectively. Joint analysis of phase 1 and 2 data, which allowed using all stage 1 data, resulted in a comparison of 310 cases and 880 controls, improved the power to 88 and 41%, respectively.
Selection of myelin-related genes
Based on an extensive literature search, we compiled a list of genes with various myelin-related functions, including structural, compositional, developmental and maintenance functions (Supplementary Table 1 ). Myelin is formed by oligodendrocytes and mainly consists of specific proteins and lipids. We compiled a list of 14 genes coding for important myelin proteins and 10 genes involved in the metabolism of important myelin lipids (for example, glycolipids and phospholipids). We added 27 genes involved in the PIsignaling pathway. Several myelin-related genes have been reported to be differentially expressed in schizophrenia patients compared to healthy controls. Specifically, seven genes CNP, ERBB3, GSN, MAG, MAL, MLP and TF were reported to be downregulated in schizophrenia patients; these were added to the list. We also included genes involved in oligodendrocyte signaling and development, and genes that were known to cause demyelinating disorders (for example, ARSA and PSAP, both involved in metachromatic leukodystrophy).
Next, we recursively expanded the list of genes by including known transcription factors and other genes and gene products interacting with the genes already on our list. Hence, we finally constructed a pathway comprised of 138 genes that were all directly or indirectly related to myelin structure, composition, development or maintenance ( Figure 1 ).
TagSNP selection
Polymorphisms used for genotyping were identified from the HapMap project data (http://www.hapmap. org). 25, 26 For this study we considered all SNPs that were genotyped in the CEU panel (Utah residents with ancestry from Northern and Western Europe) and that were located in the genomic sequence of the 138 genes, including an additional 5 kb from the 5 0 -end of the gene to include putative promoter regions. Together the 138 genes comprised 1.53 Mb of genomic sequence and harbored 3973 SNPs with minor allele frequencies > 5% (based on the CEU panel, HapMap project, data release no. 14, December 2004, on NCBI B34 assembly, dbSNP b121).
For introns with lengths over 50 kb, we excluded SNPs at distances X5 kb from the splice sites. By doing so, we reduced the number of SNPs, but still retained those polymorphisms that may influence mRNA splicing. The number of SNPs for genotyping was further reduced by eliminating information redundancy based on linkage disequilibrium (LD) between SNPs as observed in the CEU panel of the HapMap project. For each gene, we selected tagSNPs for genotyping using the Tagger program (available at http://www.broad.mit.edu/mpg/tagger). 27 We set parameters to capture all common variants (MAFX0.05) in these genes with r 2 X0.8. To improve the genotyping success rate, SNP design scores were evaluated during tagSNP selection. The design scores were provided by Illumina Inc. (San Diego, CA, USA) and reflect the probability that the corresponding SNP will perform well in the genotyping assay.
Genes that required more than 10 tagging SNPs (n = 30 genes) with the above parameters were reevaluated with more relaxed tagging parameters: MAFX0.05 and r 2 X0.5. With these parameters fewer tagging SNPs were selected and tagging was less stringent, although it should be noted that the average r 2 value between a tagSNP and any SNP it captured still exceeded 0.8. Eventually, we had selected a final set of 771 tagSNPs.
Genotyping
In stage 1, SNP genotyping was performed for individual samples using the GoldenGate assay on an Illumina BeadStation 500 GX (Illumina Inc.). Cases and controls were always grouped on the same plate. In this stage we had the availability of Assay quality scored by GenCall (v6.1.3.28; Illumina Inc.). Genotyping accuracy was determined by including the control samples on the plates: one control sample was loaded on all plates; nine samples were loaded in duplo. Based on the concordance rate of the genotype callings for these samples, the accuracy was shown to be > 99.9%. All tagSNPs were examined for their resulting quality. In total, our assay contained 771 SNPs, of which 24 SNPs (3.1%) were excluded from further analysis because of too low signals, scatter or multiple clusters (using GenCall).
In phase 2, we analyzed the 17 SNPs that had had P-values < 0.01 in phase 1. We genotyped 15 SNPs using an Assay on Demand or Assay by Design (Applied Biosystems, Foster City, CA, USA) on a 7900 Taqman (Applied Biosystems) (Supplementary Table 2 ). Two SNPs were genotyped through resequencing of PCR products using custom-made primers. Sequence reactions were carried out using BigDye chemistry (Applied Biosystems) and were analyzed using an ABI3730 automated sequencer.
Statistical analyses
To help exclude SNPs with genotyping aberrations from the analysis, Hardy-Weinberg equilibrium tests were carried out separately in cases and controls. SNPs demonstrating a significant deviation from Hardy-Weinberg equilibrium in controls (Pp0.01) were excluded from further analysis.
For all autosomal SNPs, association w 2 -values with two-tailed P-values were calculated using the Haploview program. 28 Single marker association and corresponding P-values for X-linked SNPs were calculated on likelihood ratio tests in a log-linear model using Cocaphase (Unphased package). 29 We used Bonferroni correction for both stages for 771 independent tests (SNPs) to define significant association per SNP (Pp6.5 Â 10-5). Since we observed relatively many SNPs with P < 0.01, namely 17 where 8 would have been expected based on chance, we applied an arbitrary cutoff threshold of Pp0.01 to select SNPs for inclusion in phase 2. These SNPs were considered as suggestive associations.
Stage 2 consisted of genotyping an independent set of 360 control samples and then a combined analysis of all genotypes generated in stages 1 and 2, that is, 310 cases and 880 controls. Any SNP that demonstrated marked differences (Pp0.01) in allele frequencies between stage 1 and stage 2 controls was excluded from further analysis. For SNPs tested in stage 2, the differences in odds ratio (OR) with 95% confidence intervals (CI) were assessed using the allele that showed a lower frequency in controls than in cases as a reference. Haplotype analysis was performed for those genes for which two or more tagSNPs were significantly associated. Haploview The population attributable risk (PAR) for the SNPs for which there was still association after combining stages 1 and 2 was calculated using the following formula: PAR = q(ORÀ1)/(q(ORÀ1) þ 1), where q is the population fraction with the risk factor and OR the odds ratio.
30,31
Results
In stage 1, we compared the allele frequencies of 741 SNPs from 138 myelin-related genes between 310 schizophrenia cases and 520 controls. We ranked the SNPs according to their observed P-values (Supplementary Table 3 ) and applied a Bonferroni correction. Only SNP rs165793 survived the threshold of P < 6.5 Â 10
À5
. An additional 16 SNPs were selected for stage 2 based on the arbitrary cutoff threshold of Pp0.01 (Table 1) . In stage 2, SNP genotypes were obtained for 360 additional controls, resulting in a total of 880 control samples. For rs3793753 in PIP5K2A, allele frequencies in the second control cohort deviated significantly from those in the first control cohort (P = 0.006) and this SNP was therefore omitted from further analysis.
Association analysis of 310 cases vs 880 controls resulted in improved P-values for six SNPs from three genes. In PIK4CA, four SNPs showed improved P-values, of which three reached the Bonferroniadjusted significance level of 6.5 Â 10
. Here, the data from our study sample (Figure 2 ) and the Hapmap show considerable LD for markers spanning the entire gene region. Accordingly, we reasoned that testing of additional SNPs at this stage and in this sample was not likely to provide further supporting evidence. Hence, our data show that PIK4CA is significantly associated with the risk of developing schizophrenia in the Dutch population (OR = 1.54; 95%CI = 1.28-1.86, PAR = 28%).
ARHGEF10 and FGFR1 both had one SNP for which the association P-value improved and remained below the suggestive association level (Pp0.01). SNPs from FGF1, PIK3C2G and PSAP remained at the suggestive level (Pp0.01). For several SNPs we observed that the extra controls led to slight deviations of the P-values from stage 1. This was not unexpected: the sample size of the controls in both stages was relatively small. This resulted in fluctuating allele frequencies when separate case-control analyses were performed. Accordingly, we performed a joint analysis as explained in the 'Study design'. Ideally, all control samples would have been available from the beginning, yielding more reliable data for all SNPs.
Haplotypes were estimated for FGFR1, PSAP (two SNPs each) and PIK4CA (four SNPs). Using the haplotype with the highest prevalence in controls as the reference haplotype, association P-values were calculated for each haplotype ( Table 2 ). The significance for the PIK4CA association was maintained for the derived AATG haplotype. For FGFR1 and PSAP, haplotype analysis was no better than single SNP analysis.
Discussion
To identify genes in the myelin pathway that contribute to the risk of developing schizophrenia, we screened 138 myelin-related genes in a twostage design for genetic association. Three SNPs from PIK4CA showed significant association with schizophrenia in the Dutch population (OR = 1.54; 95%CI = 1.28-1.86; PAR = 28%).
In this study, we applied a Bonferroni corrected, experiment-wide, significance level of 0.05/771 (6.5 Â 10
À5
). It is obvious that this is most conservative. However, the SNPs used in this study were selected from a limited number of candidate loci in close proximity to each other and are therefore clearly not completely independent. We subsequently applied a more relaxed threshold of Pp0.01 to identify suggestive association. This led to us identifying seven SNPs in five more genes (ARHGEF10, FGF1, FGFR1, PIK3C2G and PSAP) with suggestive evidence for association (at Pp0.01).
The most compelling evidence in this targeted pathway approach is the association of PI 4-kinase, catalytic, a (PIK4Ca). Three possibly functional variants in PIK4CA were analyzed previously without success, 32 most likely due to the small sample size or noninvolvement of the investigated variants. In contrast, our data demonstrate that the positional and functional candidate gene PIK4CA contributes to susceptibility for schizophrenia in the Dutch population. PIK4CA maps to 22q11, a chromosomal region consistently linked to both schizophrenia and bipolar disorder [33] [34] [35] for overview. Hemizygous deletions of this region cause the 22q11.2 deletion syndrome. Patients with this syndrome show a high prevalence of severe psychotic and affective disorders similar to both schizophrenia and bipolar disorder. 36 Our findings of association, as well as the location of the gene in a region previously implicated in neuropsychiatric traits, make PIK4CA a strong candidate gene for schizophrenia susceptibility. Interestingly, PIK4CA is located within 1 kb of another gene with suggestive evidence for involvement in schizophrenia, namely SNAP29. A polymorphism in the SNAP29 promoter region was found to be associated with schizophrenia in two different studies. 37, 38 Interestingly, this polymorphism is also located in the first intron of PIK4CA. It may well be that the actual signal observed in the previous studies is due to strong LD between SNAP29 and PIK4CA gene variants and that it represents the same susceptibility locus identified in this study.
PIK4CA is also a good functional candidate: it is a member of the PI cycling pathway that is inhibited by lithium, a molecule used in the treatment of mood disorders. In stage 1 of this study, three more genes from the PI cycling pathway were selected for typing in stage 2, including PIP5K2A and PIK3C2G. For PIP5K2A we have previously reported association to schizophrenia. 20 The associated SNP (rs10828317) was tested in the same patient cohort (308 patients against 580 controls, P = 4.0 Â 10
À4
) and hence not included in this study. For PIK3C2G too, we observed suggestive association (OR = 1.48, 95%CI = 1.17-1.88). Phosphoinositide 3-kinases such as PIK3C2G regulate diverse cellular responses, including cell migration, intracellular protein trafficking, control of neurite outgrowth and growth cone motility. [39] [40] [41] In general, PI-phosphates are highly relevant signaling molecules with several functions, including modification of intracellular calcium levels, signal transduction, cytoskeletal regulation, exocytosis and trafficking of vesicles. [42] [43] [44] [45] Consequently, genetic differences in PI cycling components can influence the regulation of several processes. In addition to direct effects on intracellular calcium levels and signal transduction, PI cycling may influence the cell shape of neurons or oligodendrocytes through cytoskeletal regulation. Postmortem examination of schizophrenic brains has demonstrated structural abnormalities in both myelin sheaths and oligodendroglia and it has been hypothesized that oligodendroglial dysfunction induces abnormalities in myelin, thereby contributing to the disease etiology. [46] [47] [48] Alternatively, aberrant PI levels may influence vesicle trafficking and vesicle cycling, important determinants in neurotransmitter cycling. Hence, PI kinase genes (including PIK4CA, PIP5K2A and PIK3C2G) are functional candidates for contributing to the risk of developing schizophrenia.
We observed suggestive association of both FGF1 (OR = 1.33, 95%CI = 1.1-1.6) and its receptor FGFR1 (OR = 1.3, 95%CI = 1.09-1.58) with the risk of developing schizophrenia. Both genes are highly expressed in nervous tissue. FGF1 maps to 5q31 and FGFR1 maps to 8p11 and, again, both regions have been reported as linkage regions for schizophrenia. [49] [50] [51] Overall, this circumstantial evidence and the suggestive association we observed for both genes hints at the FGF signaling pathway being involved in schizophrenia.
ARHGEF10 (r guanine exchange factor 10) has been implicated in neural morphogenesis and connectivity. Here, we have demonstrated suggestive association of rs11136442, located in ARHGEF10, to schizophrenia (OR = 1.38, 95%CI = 1.15-1.97).
PSAP (prosaposin) encodes four sphingolipid activator proteins. 52 PSAP also has additional functions unrelated to sphingolipid catabolism, including neurotrophic functions. 53 PSAP has been implicated in metachromatic leukodystrophy, a disorder with psychiatric symptoms that may mimic schizophrenia. PSAP maps to 10q22, a region where linkage has been observed to both schizophrenia and bipolar disorder. 54, 55 In this study, we observed suggestive association with two SNPs in PSAP (OR = 1.31, 95%CI = 1.09-1.58; OR = 1.35, 95%CI = 1.11-1.63).
We did not detect any positive signals for myelinrelated genes that have been implicated in schizophrenia by others (for example, CNP 56 and OLIG2 57 ). Clearly, this may have several causes, for example, limited power of our study as consequence of the sample size, population heterogeneity between the Dutch and UK studies and occurrence of type 1 errors in the original studies.
In conclusion, our study covered a pathway of 138 myelin-related genes. We observed significant association of PIK4CA to the risk of developing schizophrenia, showing that our approach of reconstructing a network or pathway of genes relevant to myelin (the putatively affected tissue) did indeed lead to the discovery of a novel schizophrenia gene. The relevance of our pathway approach is further strengthened by our identification of five more genes that show suggestive association and tend to cluster in parts of the pathway. Among the six associated genes are two genes related to PI signaling (PIK3C2G and PIK4CA), and two related to fibroblast growth factors (FGF1 and FGFR1). These clustered positive findings, in the pathway of myelin-related genes, suggest the gene clusters (that is, the myelin-related genes) play a role in schizophrenia pathology and stress the relevance of a pathway-oriented study design. To pursue the significant PIK4CA association and validate the role of other genes from this pathway in schizophrenia (genes which may have already been implicated in this study, although the results are not yet significant), we would like to see our results replicated in an independent schizophrenia sample. To this end, we are working hard to collect substantial numbers of extra schizophrenia patients.
